PTCD3

Across TCGA pan-cancer cohorts, PTCD3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PTCD3 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PTCD3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PTCD3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and COAD are the cancer types where PTCD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.851	0.546	.013	23	view →
PDAC	DFS	Quartile	All	0.549	0.197	.015	7	view →
COAD	DFS	Median	All	1.000	0.921	.016	6	view →
GBM	OS	Median	All	0.854	0.778	.019	6	view →
UCEC	DFS	Median	II,III,IV	0.549	0.867	.046	4	view →
CCRCC	OS	Quartile	All	0.959	0.820	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PTCD3–LSCC (DFS)

Open the LSCC breakdown →